Histopathology and Molecular Pathology of Vitiligo
暂无分享,去创建一个
[1] A. Yadav,et al. Clinicopathologic Analysis of Stable and Unstable Vitiligo: A Study of 66 Cases , 2016, The American Journal of dermatopathology.
[2] M. Picardo,et al. On the pathophysiology of vitiligo: possible treatment options. , 2012, Indian journal of dermatology, venereology and leprology.
[3] Meaghan Daly,et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. , 2011, Journal of the American Academy of Dermatology.
[4] N. Bagherani,et al. HYPOTHESIS: ZINC CAN BE EFFECTIVE IN TREATMENT OF VITILIGO , 2011, Indian journal of dermatology.
[5] N. Bagherani,et al. Vitiligo: A review of the published work , 2011, The Journal of dermatology.
[6] O. Shaker,et al. Role of interleukin‐17 in the pathogenesis of vitiligo , 2011, Clinical and experimental dermatology.
[7] A. Ökten,et al. Relevance of autoimmune thyroiditis in children and adolescents with vitiligo , 2011, International journal of dermatology.
[8] D. Gawkrodger,et al. Autoantibodies against tyrosine hydroxylase in patients with non‐segmental (generalised) vitiligo , 2011, Experimental dermatology.
[9] L. Naldi,et al. Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.
[10] C. Melief,et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. , 2009, The Journal of investigative dermatology.
[11] G. Lauzon,et al. Analysis of interleukin‐10 levels in lesions of vitiligo following treatment with topical tacrolimus , 2009, The British journal of dermatology.
[12] H. Attia,et al. Antioxidant enzymes and lipid peroxidation at the tissue level in patients with stable and active vitiligo , 2009, International journal of dermatology.
[13] Rebat M Halder,et al. Vitiligo update. , 2009, Seminars in cutaneous medicine and surgery.
[14] N. J. Gibbons,et al. Presence of epidermal allantoin further supports oxidative stress in vitiligo , 2008, Experimental dermatology.
[15] Eun-So Lee,et al. Histopathologic Features in Vitiligo , 2008, The American Journal of dermatopathology.
[16] E. Dellambra,et al. Keratinocyte cultures from involved skin in vitiligo patients show an impaired in vitro behaviour. , 2007, Pigment cell research.
[17] L. Manolache,et al. Stress in patients with alopecia areata and vitiligo , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.
[18] A. Traoré,et al. Vitiligo sur peau noire associé au VIH et repigmentation lors du traitement antirétroviral , 2007 .
[19] R. Mıstık,et al. Is there any relation between vitiligo and cytomegalovirus? , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.
[20] A. Taïeb,et al. [Vitiligo in a black patient associated with HIV infection and repigmentation under antiretroviral therapy]. , 2007, Annales de dermatologie et de venereologie.
[21] Wei Zhou,et al. MHC haplotypic association in Chinese Han patients with vitiligo , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.
[22] Turki Hamida,et al. A comparative study of oxidant–antioxidant status in stable and active vitiligo patients , 2006, Archives of Dermatological Research.
[23] R. Yehuda,et al. Plasma Neuropeptide Y Concentrations in Combat Exposed Veterans: Relationship to Trauma Exposure, Recovery from PTSD, and Coping , 2006, Biological Psychiatry.
[24] R. Robati,et al. Anti-thyroid peroxidase antibody and vitiligo: a controlled study , 2006, BMC dermatology.
[25] M. Namazi. Phenytoin as a novel anti-vitiligo weapon , 2005, Journal of autoimmune diseases.
[26] M. Herlyn,et al. Normal human melanocyte homeostasis as a paradigm for understanding melanoma. , 2005, The journal of investigative dermatology. Symposium proceedings.
[27] Nan-Hyung Kim,et al. Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may cause passive melanocyte death in vitiligo. , 2005, The Journal of investigative dermatology.
[28] Y. Youm,et al. Keratinocytes in the depigmented epidermis of vitiligo are more vulnerable to trauma (suction) than keratinocytes in the normally pigmented epidermis, resulting in their apoptosis , 2004, The British journal of dermatology.
[29] B. Barutcuoglu,et al. Is There Any Relationship Between Hepatitis C Virus and Vitiligo? , 2004, Journal of clinical gastroenterology.
[30] R. Morris,et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. , 2004, Journal of the American Academy of Dermatology.
[31] N. J. Gibbons,et al. Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress. , 2004, The Journal of investigative dermatology.
[32] A. Taïeb,et al. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? , 2003, Pigment cell research.
[33] F. Benvenuto,et al. Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. , 2003, The Journal of investigative dermatology.
[34] R. Spritz,et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. , 2003, Pigment cell research.
[35] G. Ogg,et al. Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo , 2003, Laboratory Investigation.
[36] L. Hale. Zinc α-2-glycoprotein Regulates Melanin Production by Normal and Malignant Melanocytes , 2002 .
[37] L. Hale. Zinc alpha-2-glycoprotein regulates melanin production by normal and malignant melanocytes. , 2002, The Journal of investigative dermatology.
[38] W. Westerhof,et al. Local Immune Response in Skin of Generalized Vitiligo Patients , 2000, Laboratory Investigation.
[39] C. Yu,et al. Cutaneous blood flow and adrenoceptor response increase in segmental-type vitiligo lesions. , 2000, Journal of dermatological science.
[40] S. Handa,et al. Vitiligo: Clinical Findings in 1436 Patients , 1999, The Journal of dermatology.
[41] I. L. Le Poole,et al. Microscopic changes in vitiligo. , 1997, Clinics in dermatology.
[42] W. Westerhof,et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. , 1996, The American journal of pathology.
[43] D. Gawkrodger,et al. Neuropeptide and neuronal marker studies in vitiligo , 1994, The British journal of dermatology.
[44] W. Westerhof,et al. Review of the etiopathomechanism of vitiligo: A convergence theory , 1993, Experimental dermatology.
[45] W. Westerhof,et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. , 1993, The Journal of investigative dermatology.
[46] J. Bystryn,et al. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. , 1991, The Journal of investigative dermatology.
[47] E. Medrano,et al. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. , 1991, The Journal of investigative dermatology.
[48] R. Koranne,et al. Vitiligo , 1988 .
[49] K. Sharquie. Vitiligo , 1984 .
[50] J. Nordlund,et al. Vitiligo: It Is Important , 1982 .
[51] J. Nordlund,et al. Vitiligo. What is it? Is it important? , 1978, JAMA.
[52] A. Lerner. Part V: Clinical Applications of Psoralens, and Related Materials: Vitiligo11From the Section of Dermatology, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut. , 1959 .